Share this article
A leading France-based gene therapy organization partnered with TFS HealthScience, a leading, global, full-service contract research organization (CRO), to navigate the complexities of conducting clinical trials for Duchenne Muscular Dystrophy (DMD) gene therapy. The collaboration successfully addressed challenges related to site selection, patient recruitment, and regulatory compliance, leading to significant progress in the trials. This case study details the strategic approach taken by TFS to ensure the trials met their goals, ultimately advancing research in a critical area of unmet medical need.
What You’ll Learn:
- The unique challenges of conducting DMD gene therapy trials
- How TFS effectively managed site selection and patient recruitment
- Strategies for navigating complex regulatory requirements across different countries
- The impactful results achieved through the collaboration between the sponsor and TFS